Preparation and Characterization of Poly Lactide-co-glycolide Nanoparticles of SN-38 | PDA Journal of Pharmaceutical Science and Technology

References

1.↵
1. Kunii R.,
2. Onishi H.,
3. Ueki K.,
4. Koyama K.,
5. Machida Y.
Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG-PPG-PEG) nanoparticles. Drug Delivery 2008, 15 ( 1), 3– 10.
OpenUrl PubMed Google Scholar
2.↵
1. Noda K.,
2. Nishiwaki Y.,
3. Kawahara M.,
4. Negoro S.,
5. Sugiura T.,
6. Yokoyama A.,
7. Fukuoka M.,
8. Mori K.,
9. Watanabe K.,
10. Tamura T.,
11. Yamamoto S.,
12. Saijo N
Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002, 346 ( 2), 85– 91.
OpenUrl CrossRef PubMed Web of Science Google Scholar
3.↵
1. Negoro S.,
2. Masuda N.,
3. Takada Y.
CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer 2003, 88 ( 3), 335.
Google Scholar
4.↵
1. Bodurka D. C.,
2. Levenback C.,
3. Wolf J. K.
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. 2003, 21 ( 2), 291– 297.
OpenUrl Abstract/FREE Full Text Google Scholar
5.↵
Physician Desk Reference, Camptosar®, 57th ed. Thomson Healthcare, Montvale, N.J, 2003.
Google Scholar
6.↵
1. Rothenberg M. L.,
2. Kuhn J. G.,
3. Burris H. A., 3rd,
4. Nelson J.,
5. Eckardt J. R.,
6. Tristan-Morales M.,
7. Hilsenbeck S. G.,
8. Weiss G. R.,
9. Smith L. S.,
10. Rodriguez G. I.,
11. Rock M. K.,
12. Von Hoff D. D.
Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 1993, 11 ( 11), 2194– 2204.
OpenUrl Abstract/FREE Full Text Google Scholar
7.↵
1. Slatter J. G.,
2. Schaff L. J.,
3. Sams J. P.
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patients. Drug. Metab. Dispos. 2000, 28 ( 4), 423– 433.
OpenUrl Abstract/FREE Full Text Google Scholar
8.↵
1. Gupta E.,
2. Lestingi T. M.,
3. Mick R.,
4. Ramirez J.,
5. Vokes E. E.,
6. Ratain M. J.
Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 1994, 54 ( 14), 3723– 3725.
OpenUrl Abstract/FREE Full Text Google Scholar
9.↵
1. Koizumi F.,
2. Kitagawa M.,
3. Negishi T.,
4. Onda T.,
5. Matsumota S.,
6. Hamaguchi T.,
7. Matsumura Y.
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006, 66 ( 20), 10048– 10056.
OpenUrl Abstract/FREE Full Text Google Scholar
10.↵
1. Chabner B. A.,
2. Longo D. L.
1. Takimoto C. H.,
2. Arbuck S. G.
Topoisomerase I targeting agents: The camptothecins. In Cancer Chemotherapy and Biotherapy: Principles and Practice; 3rd ed.; Chabner B. A., Longo D. L.Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2001; p 579.
Google Scholar
11.↵
1. Zhang J. A.,
2. Xuan T.,
3. Ma M.,
4. Parmer L.,
5. Ugwu S.,
6. Ali S.,
7. Ahmad I.
Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 2004, 270 ( 1–2), 93– 107.
OpenUrl CrossRef PubMed Google Scholar
12.↵
1. Lie S.,
2. Chien P. Y.,
3. Sheikh S.,
4. Zhang A.,
5. Ali S.,
6. Ahmad I.
Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs 2004, 15 ( 8), 773– 778.
OpenUrl CrossRef PubMed Google Scholar
13.↵
1. Onishi Y.,
2. Machida Y.
Antitumor properties of irinotecan-containing nanoparticles prepared using poly (DL-lactic acid) and poly (ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol. Pharm. Bull. 2003, 26 ( 1), 116.
Google Scholar
14.↵
1. Esmaeili F.,
2. Hosseini-Nasr M.,
3. Rad-Malekshahi M.,
4. Samadi N.,
5. Atyabi F.,
6. Dinarvand R.
Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine: Nanotech. Biol. Medicine 2007, 3 ( 2), 161– 167.
OpenUrl Google Scholar
15.↵
1. Esmaeili F.,
2. Ghahremani M. H.,
3. Ostad S. N.,
4. Atyabi F.,
5. Seyedabadi M.,
6. Malekshahi M. R.,
7. Amini M.,
8. Dinarvand R.
Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Targeting 2008, 16 ( 5), 415– 423.
OpenUrl Google Scholar
16.↵
1. Esmaeili F.,
2. Ghahremani B.,
3. Esmaeili B.,
4. Khoshayand M. R.,
5. Atyabi F.,
6. Dinarvand R.
PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int. J. Pharm. 2008, 349 ( 1–2), 249– 255.
OpenUrl PubMed Google Scholar
17.↵
1. Lockman R.,
2. Mumper R. J.,
3. Khan M. A.,
4. Allen D. D.
Nanoparticles technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 2002, 28 ( 1), 1– 13.
OpenUrl CrossRef PubMed Web of Science Google Scholar
18.↵
1. Grief R.,
2. Domb A.,
3. Quellec P.,
4. Blunk T.,
5. Müller R. H.,
6. Verbavatz J. M.,
7. Langer R.
The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Del. Rev. 1995, 16 ( 2–3), 215– 233.
OpenUrl CrossRef Google Scholar
19.↵
1. Cappel J.,
2. Kreuter J.
Effect of nanoparticles on transdermal drug delivery. J. Microencapsul. 1991, 8 ( 3), 369– 374.
OpenUrl PubMed Google Scholar
20.↵
1. Arica B.,
2. Lamprecht A.
In vitro evaluation of betamethasone-loaded nanoparticles. Drug Del. Ind. Pharm. 2005, 31 ( 1), 19– 24.
OpenUrl Google Scholar
21.↵
1. Pal A.
Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 2005, 25 ( 1A), 331– 341.
OpenUrl Abstract/FREE Full Text Google Scholar
22.↵
1. Sumitomo M.,
2. Koizumi F.,
3. Asano T.,
4. Horiguchi A.,
5. Ito K.,
6. Kakizoe T.,
7. Hayakawa M.,
8. Matsumura Y.
Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res. 2008, 68 ( 6), 1631– 1635.
OpenUrl Abstract/FREE Full Text Google Scholar
23.↵
1. Soppimath K. S.,
2. Aminabhavi T. M.,
3. Kulkarni A. R.,
4. Rudzinski W. E.
Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled Release 70 ( 1–2), 1– 20.
Google Scholar
24.↵
1. Mu L.,
2. Feng S. S.
A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Controlled Release 2003, 86 ( 1), 33– 48.
OpenUrl CrossRef PubMed Web of Science Google Scholar
25.↵
1. Dong Y.,
2. Feng S. S.
Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25 ( 14), 2843– 2849.
OpenUrl CrossRef PubMed Google Scholar
26.↵
1. Murakami H.,
2. Kobayashi M.,
3. Takeuchi Y.,
4. Kawashima Y.
Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 1999, 187 ( 2), 143– 152.
OpenUrl CrossRef PubMed Google Scholar
27.↵
1. Niwa T.,
2. Takeuchi H.,
3. Hino T.,
4. Kunou N.,
5. Kawashima Y.
In vitro drug release behavior of D, L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J. Pharm. Sci. 1994, 83 ( 5), 727– 732.
OpenUrl CrossRef PubMed Web of Science Google Scholar
28.↵
1. Le Roy Boehm A. L.,
2. Zerrouk R.,
3. Fessi H.
Poly epsilon-caprolactone nanoparticles containing a poorly soluble pesticide: Formulation and stability study. J. Microencapsul. 2000, 17 ( 2), 195– 205.
OpenUrl PubMed Google Scholar
29.↵
1. Paul M.,
2. Laatiris A.,
3. Fessi H.,
4. Dufeu B.,
5. Durand B.,
6. Deniau M.,
7. Astier A.
Pentamidine-loaded poly(D, L-lactide) nanoparticles: Adsorption and drug release. Drug Dev Res. 1998, 43 ( 2), 98– 104.
OpenUrl Google Scholar
30.↵
1. Garderton D.,
2. Jones T.
1. Holland S. J.,
2. Tighe B. J.
Biodegradable Polymers. In Advanced Pharmaceutical Science; Garderton D., Jones T.Eds; Academic Press: New York, 1992; Vol. 6, p 101.
OpenUrl Google Scholar